Tobacco Funding & Scientific Research

Workshop

Ethical, Legal and Policy Issues

February 22-23, 2003
New Orleans

Sponsored by:

American Legacy Foundation
California Tobacco-Related Disease Research Program
National Cancer Institute

PM3006501317

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Workshop on Tobacco Industry Funding and Scientific Research:

Ethical, Legal and Policy Issues

Participant Contact Sheet

February 22 – 23, 2003
The Sheraton, Downtown New Orleans

Note: *This information was taken from the disclosure forms filled out at registration. If you would like to make any changes or updates, please email them to Allison Nambu at* ***allison@pyramidcommunications.com*** *by* ***March 14, 2003****. We will then send a new contact list to all workshop participants.*

PM3006501318

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Abu Abdullah
Assistant Research Professor
University of Hong Kong
Faculty of Medicine
5/F Academic Block
21 Sassoon Road
Pokfulam, Hong Kong
P: (00852) 28199280
asma@hkucc.hkn.hk

Candace Adams
Senior Research Scientist
Philip Morris, USA Inc.
R&D/A2, 615 Maury Street
Richmond, VA 23224
P: (804) 274-2664
F: (804) 274-2891
candace.r.adams@pmusa.com

Tony Albino
Vice President of Public Health Affairs
Vector Group, LTD
712 5th Avenue
New York, NY 10019
P: (212) 409-2800
F: (212)409-2801
talbino@vectorgroupLTD.com

Paula-Rita Alphonse
Policy Analyst
Health Canada
123 Slater
Ottowa-Ontario, Canada
P: (613) 952-5373
F: (612) 952-5188
palphons@hc-sc.gc.ca

Susan Anderson
University of Stratchlyde
173 Cathedral Street
Glasgow, Scotland GW ORQ
P: (44) 141-548-3060
F: (44) 141 -53-4118
s.anderson@csm.market.strath.ac.uk

Scott Appleton
Director of Scientific and
Regulatory Affairs
Brown & Williamson Tobacco
Corporation
1123 Lucky Debonair Drive
Mawn, GA
P: (478) 464-3574
scott_appleton@bat.com

Linda Bailey
Director
Center for Tobacco Cessation
901 East Street NW, Suite 500
Washington, DC 20004
P: (202) 661--5700
F: (202) 661-5750
linda.a.bailey@cancer.org

Joaquin Barnoya
Post Doctoral Fellow
University of California,
San Francisco
530 Pamassus Avenue
San Francisco, CA
P: (415) 476-2265
F: (415) 514-9345
jbarnoya@medicine.ucsf.edu

Matthew Barry
Senior Policy Analyst
Campaign for Tobacco-Free Kids
1400 I Street NW, Suite 1200
Washington, DC 20005
P: (202) 296-5469
F: (202) 296-5427
mbarry@tobaccofreekids.org

Dilyara Barzani
National Cancer Institute
6116 Executive Boulevard
Bethesda, MD
P: (301) 451-5043
barzanid@mail.nih.gov

PM3006501319

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ronald Bayer
Professor
Mailman School of Public Health,
Columbia University
Center for the History and Ethics of
Public Health
630 West 168th Street
New York, NY 10027
P: 212-305-1957
F: 212-305-6832
rb8@columbia.edu

Neal Benowitz
Professor of Medicine, Psychiatry and
Biopharmaceutical Services
University of California,
San Francisco
P: (415) 206-8324
nbeno@itsa.ucsf.edu

Lisa Bero
Professor
University of California,
San Francisco
Center for Tobacco Control Research
and Education, Department of
Clinical Pharmacy
3333 California Street, Suite 420
Box 0613
San Francisco, CA 94143-0613
P: (415) 476-1067
F: (415) 502-0792
bero@medicine.ucsf.edu

Richard Briere
Assistant Director
Canadian Institutes of Health
Research, Mental Health
and Addiction
6875 Lasalle Boulevard
Verdun, Canada QC H4H IR3
P: (514) 761-6131 ext. 3930
F: (514) 888-4060
richard.briere@douglas.mcgill.ca

Francisco Buchting
Research Administrator
Tobacco-Related Disease
Research Program
University of California, Office of
the President
300 Lakeside Drive, 6th Floor
Oakland, CA 94612
P: (510) 987-9883
F: (510) 835-4740
francisco.buchting@ucop.edu

David Burns
Professor of Medicine
University of California, San Diego
School of Medicine
1545 Hotel Circle S., Suite 310
San Diego, CA 92108
P: 619-294-6453
F: 619-220-0228
dburns@ucsd.edu

Sharon Carothers
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5563

Jeffrey Cheek
Director
Colorado Tobacco Research Program
4001 Discovery Drive, Suite 230,
CB 588
Boulder, CO 80309
P: (303) 492-5955
jeff.cheek@cu.edu

Created by Pyramid Communications
2/23/03

PM3006501320

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Pamela Clark
Senior Research Scientist
Battelle Centers for Public Health
Research & Evaluation
6115 Falls Road, 2nd Floor
Baltimore, MD 21209
P: (410) 372-2750
F: (410) 377-6803
clarkp@battelle.org

Christopher Cook
Director of Applied Research
Brown & Williamson Tobacco Co.
2600 Weaver Road
Mawn, GA 31217
P: (478) 464-3455
chris_cook@bat.com

Michael Cummings
Chairman
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263
P: 716-845-8456
F: 716-845-8487
michael.cummings@roswellpark.org

Anthony Curcio, Jr.
Jacob Medinger & Finegan
270 Avenue of the Americans
P: (212) 332-7757
F: (212) 332-7777
acurcio@jmfnylaw.com

Richard Daynard
Professor of Law
Northeastern University
School of Law
400 Huntington Avenue
Boston, MA 02115-5000
P: (617) 373-2026
F: (617) 373-3672
r.daynard@neu.edu

Mirjana Djordjevic
National Cancer Institute
6130 Executive Boulevard, EPN 4044
Bethesda, MD
P: (301) 496-8584
F: (301)496-8675
djordjev@mail.nih.gov

David Dobbins
Associate Council
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5598
F: (202) 454-5599
ddobbins@americanlegacy.org

Edward Domino
Professor Pharmacology
University of Michigan
Department of Pharmacology
P.O. Box 0632
Ann Arbor, MI 48109
P: (734) 764-9115
F: (734) 763-4450
efdabcde@umich.edu

Gerard Dubois
Chairman
French National Committee
Against Smoking
Hospital Norol
Place V. Pauchet, 80054
Amiens, France
P: (33) 3 22668197
F: (33) 3 22668198
pr.g.dubois@wanadoo.fr

PM3006501321

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Thomas Eissenberg
Associate Professor
Virginia Commonwealth University
College of Humanities & Sciences
923 West Franklin Street
P.O. Box 842019
Richmond, VI 23281-2019
P: (804) 225-4617
teissenb@vcu.edu

Bob Ellis
Manager of Surveillance
Health Canada
PL 3507B
Ottowa, Canada 14A 0K9
P: (613) 957-0697
bob_ellis@hc-sc.gc.ca

Sarah Evans
Graduate Research Associate
Virginia Commonwealth University
P.O. Box 980205
Richmond, VA 23289-0205
P: (804) 225-3562
F: (804) 828-7862
seevcu@aol.com

Jonathan Foulds
Director & Associate Professor
UMDNJ
Tobacco Dependence Program
317 George Street
New Brunswick, NJ 08901
P: (732) 235-8213
F: (732) 235-8297
jonathan.foulds@umdnj.edu

Brion Fox
Assistant Scientist
University of Wisconsin
Comprehensive Cancer Center
385 WARF Building
610 Walnut Street
Madison, WI 53726
P: (608) 262-3894
F: (608) 262-2425
bjfox@uwccc.wisc.edu

Phillip Gardiner
Social/Behavioral Sciences
Research Administrator
Tobacco-Related Disease
Research Program
University of California, Office of the
President
300 Lakeside Drive, 6th Floor
Oakland, CA 94612
P: (510) 987-9853
F: (510) 835-4740
phillip.gardiner@ucop.edu

Hans Gilljam
Center for Tobacco Prevention
Wollmar Yxkullsgatan 19, S-11891
Stockholm, Sweden
P: (46) 8 5177 8056
F: (46) 8 51778072
hans.gilljam@smd.sll.se

Stanton Glantz
Professor of Medicine
University of California,
San Francisco
505 Parnassus Avenue, Room M1317
San Francisco, CA 94143-0130
P: (415) 476-3893
F: (415) 476-2283
glantz@medicine.ucsf.edu

PM3006501322

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Rina Hakimian
Regulatory Counsel
Association of American
Medical Colleges
Division of Biomedical and Health
Sciences Research
2450 North Street NW
Washington, DC 20037
P: 202-828-0484
F: 202-828-1125
rhakimian@aamc.org

David Hamilton
Project Manager
Pyramid Communications
1932 1st Avenue, Suite 507
Seattle, WA 98101
P: (206) 792-0420
F: (206) 374-7798
daveh@pyramidcommunications.com

Dorothy Hatsukami
Professor
Tobacco Use Research Center
University of Minnesota
2701 University Avenue SE
Minneapolis, MN 55414
P: (612) 627-1808
F: (612) 627-4899
hatsu001@maroon.tc.umn.edu

Lyndon Haviland
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: 202-454-5565
F: 202-454-5599
lhaviland@americanlegacy.org

Cheryl Healton
President and Chief Executive Officer
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5500
F: (202) 454-5599
chealton@americanlegacy.org

Norbert Hirschhorn
Independent Consultant
1044 Chapel Street, #502
New Haven, CT 06510
P: (203) 777-8688
bertzpoet@yahoo.com

Martina Hone
Associate Counsel for Public Policy
and Government Relations
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5751
F: (202) 454-5769
mhone@americanlegacy.org

Mi-Kyung Hong
Research Analyst
University of California,
San Francisco
Center for Tobacco Control
Research and Education
530 Parnassus Avenue, Suite 366,
Box 1390
San Francisco, CA 94143-1390
P: (415) 502-8203
F: (415) 514-9345
mkhong@itsa.ucsf.edu

PM3006501323

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

John Hughes
Professor of Psychiatry
University of Vermont
College of Medicine
Burlington, VT 05405
P: (802) 656-9610
john.hughes@uvm.edu

Roger Jenkins
Distinguished ROD Staff Member
Oak Ridge National Laboratory
One Bethel Valley Road
Oak Ridge, TN 37831-6120
P: (865) 574-4871
F: (865) 576-7956
jenkinsra@ornl.gov

Lynn Kozlowski
Professor and Head Department of
Biobehavioral Health
Pennsylvania State University
315 East HHD
University Park, PA
P: (814) 863-7256
F: 814-863-7525
ltk1@psu.edu

Harry Lando
P:
F:

Scott Leischow
Chief, Tobacco Control
Research Branch
National Cancer Institute
Executive Plaza North
6130 Executive Boulevard MSC 7337,
Room 4038
Rockville, MD 20852-7337
P: (301) 496-8584
F: (301) 496-8675
SL83p@NIH.gov

Bruce Leistikow
Associate Adjunct Professor
University of California, Davis
Department of Epidemiology &
Preventive Medicine,
Davis, CA 95616
P: (530) 752-1409
F: (530) 752-3229
bnleistikow@ucdavis.edu

Mark Likness
President
Plowshare Technologies, Inc.
Baltimore, MD
P: (410) 342-5947
markl@plowshare.com

Stephen Marcus
Epidemiologist
National Cancer Institute
6130 Executive Boulevard,
Suite 4039 B
Bethesda, MD 20892
P: (301) 594-7934
F: (301) 496-8675
sm311j@nih.gov

Elizabeth Marren
Senior Corporate Counsel
UST, Inc.
100 West Putnam Avenue
Greenwich, CT
P: (203) 622-3548
F: (203) 661-5613

Erika Martin
University of Michigan
2822 Sagebrush, #207
Ann Arbor, MI 48103
P: (734) 936-0939
emartinz@umich.edu

PM3006501324

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

James McEnroe
P: (636) 256-4780
jmcenroe@ifish.org

Allison McKinnon
Tobacco Research Coordinator
Alberta Alcohol and Drug
Abuse Commission
10909 Jasper Avenue, 12th Floor
Edmonton-Alberta, Canada T5J 3M9
P: (780) 422-3629
F: (780) 427-0456
allison.mckinnon@aadac.gov.ab.ca

Steve McLauglin
Senior Vice President and
General Manager
Battelle Health and Human
Services Sector
1725 Jefferson Davis Highway
Crystal City, VA 22202
P: (703) 416-8162
F: (703) 416-8194
mclaughs@battelle.org

Adin Miller
Assistant Vice President of Grants
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5555
F: (202) 454-5775
amiller@americanlegacy.org

Matthew Myers
President and Chief Executive Officer
National Center for
Tobacco-Free Kids
1400 I Street, Suite 1200
Washington, DC 20005
P: (202) 296-5469
F: (202) 296-5427
mmyers@tobaccofreekids.org

Allison Nambu
Project Coordinator
Pyramid Communications
1932 1st Ave, Suite 507
Seattle, WA 98101
P: 206-792-0437
F: 206-374-7798
allison@pyramidcommunications.com

Charles Nesson
Weld Professor of Law
Harvard Law School
5 Hubbard Park Road
Cambridge, MA 02138
P: (617) 495-7547
F: (617) 495-7641
nesson@law.harvard.edu

Kathleen O'Connell
Professor
Columbia University
Teachers College
525 West 120th Street, Box 35
New York, NY 10027
P: (212) 678-3120
F: (212) 678-4048
oconnell@tc.columbia.edu

Mark Parascandola
Cancer Prevention Fellow
National Cancer Institute
6130 Executive Boulevard, Suite 3109
Bethesda, MD 20892
P: (301) 594-1576
F: (301) 402-4863
paramark@mail.nih.gov

Jaime Perez-Martin
P:
F:

PM3006501325

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Prabhu Ponshe
President
Health Matrix, Inc.
7918 Jones Branch Drive, #600
Mclean, VA 22102
P: (703) 918-4930
F: (703) 918-4931
prabhu@healthmatrixinc.com

Christopher Proctor
Head of Science and Regulation
British American Tobacco
Globe House
4 Temple Place
London, WC2R 2PG
P: 0-11-44-207-845-1218
F: 0-11-44-207-845-2783
christopher_proctor@bat.com

Bisoen Rambali
RIVM
P.O. Box 1, 3720 BA
Bihoven, Netherlands
P: (31) 30 274 4505
F: (30) 302 74446
bisoen.rambali@rivm.nl

Stephen Rennard
P: (402) 559-7313
srennard@unmc.edu

Nancy Rigotti
Director of Tobacco Research and
Treatment Center
Massachusetts General Hospital
Harvard Medical School
50 Staniford Street, 9th Floor
Boston, MA 02114
P: (617) 724-3548
F: (617) 724-3544
nrigotti@partners.org

William Riley
Director of Research
PICS
12007 Sunrise Valley Drive, Suite 480
Reston, VA 20191
P: (703) 758-1400
F: (703) 758-1799
briley@lifesignusa.com

Brad Rodu
Professor
Univeristy of Alabama, Birmingham
Department of Pathology, LHRB 156
Birmingham, AL 35294-0007
P: (205) 934-3380
F: (205) 975-5200
drrodu@drrodu.com

Hans Roethig
Director of Clinical Evaluation
Philip Morris USA, Inc.
615 Maury Street
Richmond, VA 23334
P: (804) 274-3165
F: (804) 274-2891
hans-juergen.roethig@pmusa.com

Jed Rose
Research Professor
Duke University
Medical Center, Comprehensive
Cancer Center
301 MSRB, DUMC Box 3843
Durham, NC 27710
P: (919) 684-3377
F: (919) 684-5653
jerose@acpub.duke.edu

PM3006501326

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

David Rosner
Professor of History and Public Health, and Director of the Center for the History and Ethics of Public Health
Columbia University
Mailman School of Public Health
722 West 168th Street, Room 934
New York, NY 10032
P: (212) 305-1727
F: (212) 342-1986
dr289@columbia.edu

Kathy Sanders-Phillips
Director
Howard University
Research Program, Epidemiology and Prevention of Drug Abuse
2900 Van Ness Street NW
Holycross Buildling Room. 413
Washington, DC 20008
P: (202) 806-8614
F: (202) 237-5936
ksandersphillips@aol.com

Mark Saunders
Senior Marketing Manager
GlaxoSmithKline
Consumer Healthcare
1000 GSK Drive
Moon Township, PA 15108
P: (412) 200-3439
F: (412) 249-4509
mark.saunders@gsk.com

George Schepers
Philip Morris Research Laboratory
P: (48) 2203-303334
georg.schepers@pmintl.com

Carol Schmitt
Principal Health Research Scientist
Battelle Centers for Public Health Research & Evaluation
6115 Falls Road, Suite 200
Baltimore, MD 21209
P: (410) 372-2757
F: (410) 377-6802
schmittc@battelle.org

Peter Selby
P: (416) 535-8501
peter_selby@camh.net

Neil Sherwood
Director of Scientific and Regulatory Affairs
JT International
14 Chemin Rieu, CH-1211
Geneva, Switzerland
P: (41) 22-703-0954
F: (41) 22 7033954
neil.sherwood@jt_int.com

Todd Smithers
Brand Manager
GlaxoSmithKline
P.O. Box 1467
Pittsburgh, PA 15230
P: 412-200-3447
F: 412-200-4509
todd.m.smithers.com

Richard Solana
Vice President of Worldwide Scientific Affairs
Philip Morris USA, Inc.
P.O. Box 26603
Richmond, VA 28261-6603
P: (804) 274-7181
F: (804) 274-7181
rick.p.solana@pmusa.com

PM3006501327

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Becky Steinmark
Communications Manager
American Legacy Foundation
1001 G Street NW, Suite 800
Washington, DC 20001
P: (202) 454-5561
F: (202) 454-5599
bsteinmark@americanlegacy.org

David Sweanor
Legal Counsel
Smoking and Health Action
Foundation, Canada
P: (613) 230-4211
dsweanor@nsra-adnf.ca

Anne Tillery
Managing Partner
Pyramid Communications
1932 1st Ave, Suite 507
Seattle, WA 98101
P: (206) 792-0404
F: (206) 374-7798
anne@pyramidcommunications.com

Richard Verheij
Executive Vice President and
General Counsel
U.S. Smokeless Tobacco Company
100 West Putnam Avenue
Greenwich CT, 6830
P: (203) 622-3648

Bob Vollinger
Program Director and Public
Health Advisor
National Cancer Institute
Tobacco Control Research Brand
6130 Executive Boulevard
EPN Room 4030, MSC 7337
Bethesda, MD
P: (301) 496-0275
F: (301) 496-8675
bob.vollinger@nih.gov

Roger Walk
Director of Scientific Affairs
Philip Morris, USA Inc.
Richmond, VA
P: (804) 274-4839
roger.a.walk@pmusa.com

Kay Wanke
Cancer Prevention Fellow
National Cancer Institute
6116 Executive Boulevard, #109
Bethesda, MD
P: (301) 451-5043
wankek@mail.nih.gov

Kenneth Warner
Avedis Donabedian Distinguished
University Professor of Public Health
University of Michigan
School of Public Health
109 South Observatory
Ann Arbor, MI 48109-2029
P: (734) 936-0934
F: (734) 764-4338
kwarner@umich.edu

Eric Watsky
Director
Pfizer, Inc.
50 Pequot Avenue
New Condon, CT 06320
P: (860) 752-0487

Jenny White
Research Analyst
University of California,
San Francisco
Center for Tobacco Control Research
and Education
530 Parnassus Avenue, Suite 366
San Francisco, CA
P: (415) 476-1526
jewhite@itsa.ucsf.edu

Created by Pyramid Communications
2/23/03

PM3006501328

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Chester J. Wrobleski
Partner
Jacob, Medinger & Finegan
1270 6th Avenue
New York, NY
P: (212) 332-7720
F: (212) 332-7777
cjwrobleski@jmfnylaw@iom

Mark Zehner
Research Specialist
University of Wisconsin
Medical School
Center for Tobacco Research
and Intervention
1930 Monroe Street, Suite 200
Madison, WI 53711
P: (608) 262-7567
F: (608) 265-3105
mez@ctri.medicine.wisc.edu

Mitchell Zeller
Vice President for Policy and
Strategic Communications
Pinney Associates
16737 Gooseneck Terrace
Olney, MD 20832
P: (301) 570-9326
F: (301) 570-0034
pmle@aol.com

PM3006501329

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ethical, Legal and Policy Issues

Tobacco Funding & Scientific Research

Workshop

February 22-23, 2003 *New Orleans*

Welcome

Welcome to the *Tobacco Funding and Scientific Research Workshop*. This workshop will provide an initial framework of civil and constructive dialogue to help scientists, institutions, government agencies and funding organizations to make informed decisions around issues relating to the funding of scientific research by the tobacco industry. We believe that you have a critical role to play in that dialogue.

The speakers, presenters and discussants of this workshop will initiate dialogue around the ethical, legal and policy issues raised by tobacco industry funding of scientific research. These individuals reflect the diversity of opinions around this issue.

The workshop is divided into the following areas:

- **Session #1: Ethical and Legal Perspectives – Is the tobacco industry different?**
  An in-depth discussion on the ethical and legal implications of receiving tobacco industry funding of scientific research. Discussion will also include how these issues developed with respect to other industries like pharmaceuticals, lead paint and asbestos.

- **Session #2: Research Funding Practices**
  An honest discussion reviewing pro and con perspectives from scientists about taking tobacco industry money.

- **Socratic Dialogue**
  A professionally moderated discussion that will bring together a diverse group of individuals with divergent viewpoints on tobacco funding issues to discuss what they would do in specific situations.

Thank you for participating in what we anticipate will be an interesting and mutually rewarding workshop.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501330

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

AGENDA

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ethical, Legal and Policy Issues

Tobacco Funding & Scientific Research

Workshop

Agenda

February 22-23, 2003 *New Orleans*

Saturday, February 22

6:00 p.m. – 6:30 p.m. **Welcome Reception**

6:30 p.m. – 7:30 p.m. **Program and Introductions**
Cheryl Healton, *American Legacy Foundation*

Keynote Addresses
Mitchell Zeller, *Pinney Associates* (lawyer)
Ron Bayer, *Columbia University*

Sunday, February 23

7:00 a.m. – 8:00 a.m. **Continental Breakfast**

8:00 a.m. – 8:15 a.m. **Welcome and Overview by Workshop Moderator**
Scott Leischow, *National Cancer Institute*

8:15 a.m. – 10:00 a.m. **Session #1: Ethical and Legal Perspectives**
Is the tobacco industry different?

Moderator:
Richard Daynard, *Northeastern University School of Law* (lawyer)

Presenters:
Lisa Bero, *University of California, San Francisco* (lawyer)
Brion Fox, *University of Wisconsin Comprehensive Cancer Center* (lawyer)

Discussants:
Linda Bailey, *Center for Tobacco Cessation* (lawyer)
Rina Hakimian, *Association of American Medical Colleges*

Question & Answer

10:00 a.m. – 10:15 a.m. **Break**

10:15 a.m. – 12:00 p.m. **Session #2: Research Funding Practices**
Pro and con perspectives from scientists on taking tobacco industry money

Moderator:
Kenneth Warner, *University of Michigan*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501332

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

10:15 a.m. – 12:00 p.m. **Session #2 *Continued***

Presenters:
Neal Benowitz, *University of California, San Francisco*
Jed Rose, *Duke University*

Discussants:
David Rosner, *Columbia University*
Lynn Kozlowski, *Pennsylvania State University*

Question & Answer

12:00 p.m. – 1:00 p.m. **Lunch**

Case Study Presentations:
Phillip Gardiner, *Tobacco-Related Disease Research Program, University of California, Office of the President*
Stanton Glantz, *University of California, San Francisco*

Question & Answer

1:00 p.m. – 2:45 p.m. **Socratic Dialogue**

Moderator:
Charles Nesson, *Harvard Law School*

Participants:
David Burns, *University of California, San Diego*
Pamela Clark, *Battelle Centers for Public Health Research and Evaluation*
Michael Cummings, *Roswell Park Cancer Institute*
Matthew Myers, *National Center for Tobacco-Free Kids*
Christopher Proctor, *British American Tobacco*
Nancy Rigotti, *Massachusetts General Hospital, Harvard Medical School*
Kathy Sanders-Phillips, *Howard University*
Richard Solana, *Philip Morris USA, Inc.*
David Sweanor, *Smoking and Health Action Foundation*

2:45 p.m. – 3:00 p.m. **Break**

3:00 p.m. – 3:45 p.m. **Small Group Discussion**

3:45 p.m. – 4:00 p.m. **Closing Remarks**
Cheryl Healton, *American Legacy Foundation*
Scott Leischow, *National Cancer Institute*

4:00 p.m. **Adjourn**
Note: Free airport shuttles available

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501333

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

BRIEFING
PAPER

PM3006501334

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ethical, Legal and Policy Issues

Tobacco Funding & Scientific Research

Workshop

Briefing Paper

February 22-23, 2003 New Orleans

Accepting Tobacco Industry Funding for Research: *An Overview of the Issues*

By Joanna Cohen, Ph.D., University of Toronto

I. Introduction

Today more than ever, tobacco companies have an interest in portraying a positive corporate image. Funding external research is one strategy this industry has used to counter studies demonstrating the negative effects of tobacco use and to deflect criticisms about its business practices. Although some tobacco industry-funded research has been of high quality, many studies it has sponsored on the risks of active and passive smoking have been shown not to be. Indeed, the higher quality research has focused on substances other than tobacco as a cause of adverse health outcomes; this has been called "distracting research" because it contributes to the playing down of the negative impacts of tobacco use. Further, it has been documented that many grants from tobacco industry research councils were controlled by industry lawyers rather than by scientific advisory boards and they were awarded specifically to promote research "controversies."

While the tobacco industry continues to set up external funding programs, several U.S. schools of public health and organizations that fund tobacco-related science have instituted formal policies restricting tobacco industry sponsorship of research. In September 2001, the Society for Research on Nicotine and Tobacco adopted a position statement to encourage its members not to solicit or accept support from the tobacco industry, to continue refusing support from the tobacco industry for Society activities and to "not endorse the support of its members' research or their participation in other activities funded by the tobacco industry."

There are legitimate arguments both for and against accepting tobacco industry funding for research. The purpose of this backgrounder is to provide an overview of the issues surrounding research sponsorship by the tobacco industry. Seven key issues will be discussed followed by a brief summary of what we know about university, journal and research society practices in this area. A select bibliography can be found at the end of this document.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501335

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

II. The Issues

1. Academic Freedom

Academic freedom is a key value in university settings. Some believe that imposing any boundaries on researchers, including prohibiting them from accepting funding from certain sources, is anathema to the ideals of academia. They argue that any such restriction could lead to a stifling of necessary scientific debate because there would be fewer funding options. If it is perceived that debate is curbed in any way, researchers and their institutions may eventually lose some of their credibility. It is important to note, however, that a number of boundaries are already imposed on academic research. For example, institutional review boards are federally mandated in the United States and academic research must adhere to human subjects and other ethical standards (e.g., scientific integrity, financial conflicts of interest). Further, funding agencies may place particular requirements on the use of their funds and academic institutions may also have their own rules and regulations about the conduct of research and the use of research funds. In addition to mandated requirements, scientists also have an obligation to society to identify real health problems and promote resolutions, while institutions have an obligation to undertake research that benefits mankind. Some may contend that because the tobacco industry has deliberately worked to obstruct these responsibilities, arguments claiming the coexistence of academic freedom and tobacco-funded research are moot. It could also be argued that these obligations preclude relationships with an industry that knowingly kills its customers and that has systematically suppressed, manipulated and distorted the scientific record.

2. Respectability by Association

It has been argued that recipients of tobacco funding can provide these companies with respectability and legitimacy by association. By supporting research, the tobacco industry can claim it is acting responsibly and in good faith, while at the same time generating good publicity. Indeed, this industry has pointed to the reputable institutions it has funded in an attempt to gain prestige and win the approval of juries. Recipients of tobacco funding may defend the funder's interests; more subtly, they may remain silent on issues that impact negatively on the tobacco industry. These behaviors could help contribute to tobacco company objectives that undermine public health. There are new concerns that the tobacco industry is trying to gain respectability from its associations with universities under the banner of corporate social responsibility. In 2000, British American Tobacco (BAT) donated £3.8 million for an International Center for Corporate Social Responsibility at the University of Nottingham. The following year, Imperial Tobacco in Canada, which is owned by BAT, made a contribution to a Toronto university's certificate program in corporate social responsibility.

3. Tobacco is "Special"

If universities prohibit the acceptance of tobacco money for research, will, or should, this lead to prohibiting the acceptance of research funds from tobacco sister companies or from other industries? Where should academia draw the line? Tobacco is not the only industry that has demonstrated questionable conduct. Clearly, most industries would have an economic interest in the outcomes of research they fund, resulting in a great potential for conflicts of interest. Pharmaceutical companies have shown some suspect practices vis-à-vis their relationships with academic research. For example, drug companies have "bought" journal editorials and marketing departments – rather than medical or scientific departments – fund and oversee some studies, and they have been accused of trying to ruin the careers of scientists who have publicized research findings that would be detrimental to these companies. Research has shown that having a financial relationship with a pharmaceutical company is

PM3006501336

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

strongly associated with publishing views that are favorable to this industry. The asbestos industry also funded research aimed at quelling fears about the negative health impacts of asbestos. The asbestos companies sponsored little epidemiological research or studies that explored the relationship between asbestos and cancer. The companies dictated the research strategy of the Asbestosis Research Council, vetted publications and sometimes censored publications. Despite potential influence from any corporate funder, some argue that tobacco is "special" and that this industry should be treated differently from other private sector sources. Tobacco is a unique product because it is addictive, toxic and lethal to half of its long-term users; further, the number of people harmed by tobacco worldwide is of epidemic magnitude. Moreover, tobacco industry products are not regulated like other consumer products. Historically they have been exempt from food and drug legislation, consumer product safety legislation and hazardous product legislation. Given the immense harms of tobacco industry products, and the fact that they are not required for subsistence, some argue that the tobacco industry cannot be a legitimate partner in funding scientific research.

4. Tobacco Products Are Legal

Those who support the acceptance of tobacco industry funds argue that tobacco companies are legal businesses and that their products are legal. Thus, there should be no reason for rejecting their money for research purposes. Furthermore, it can be argued that it is preferable to take tobacco money for research (a societal "good") rather than leave it in tobacco company coffers where it can be used for the marketing and promotion of tobacco products. Indeed, university-industry partnerships continue to be strongly encouraged by both government and by universities themselves. However, with revelations that industry sometimes has very strong controls over the conduct of what is supposed to be independent academic research, concerns have been raised about whether science is being driven by a responsibility to contribute to a healthy, productive and just society, or by the market place and stock prices. Some worry that if universities appear to be responding to the profit motive they will lose credibility and subsequently the public trust. In addition, some believe that the scientific community has a moral and ethical imperative not to collaborate with an industry that is increasing its presence and predatory practices in developing countries where the regulatory climate and public attitudes toward the tobacco industry are more susceptible to abuse by this industry. Although tobacco companies insist that they are better corporate citizens than ever before, at least in developed countries, their actions still do not support their words.

5. The Need for Funds

An argument in favor of allowing researchers to take tobacco funding is that there are insufficient funds to support all potentially useful research in this area. It is argued that there are no other funders that could (or would) step in to fund the type of research that tobacco companies are willing to support. Further, some believe that just as the pharmaceutical companies are required to support research to evaluate their products, tobacco companies should also be expected to fund research for the evaluation of its own products. Indeed, many are quick to criticize research about new tobacco devices when it is conducted by tobacco industry scientists. Such research may be more credible if conducted by the academic community. Currently, however, even academic scientists who take tobacco money are often suspect. This means that there is very little independent verification of claims being made by the tobacco industry about its products and there is little ability to test these products before they appear on the market. Thus, the status quo suggests that without a shift in attitudes about tobacco industry funding for research, a truly effective and acceptable harm reduction product developed by the tobacco industry, for example, could never receive support from most members of the tobacco control community, at least

PM3006501337

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

not in a timely manner. Of course if status quo views about accepting tobacco money for research change, parameters would have to be set up and enforced to ensure that full scientific independence is maintained. It may be that the best scenario for funding studies that evaluate novel tobacco industry products would be through an industry-funded neutral third-party organization responsible for adjudicating research proposals and administering the funds. Still, many argue that a need for funds is not a sufficient reason to accept sponsorship from an industry with a history of funding research aimed at promoting "controversies" and distracting attention away from tobacco's adverse health effects.

6. *Ethical Guidelines and Disclosure Policies*

Ethical guidelines exist to protect research from undue influence on the part of the funder. Further, disclosure of funding sources, the peer review process and some financial conflict-of-interest policies are often thought to be sufficient to ensure scientific impartiality. Nonetheless, industry sponsors may exert influence over the scientific process at multiple points: withholding "negative" findings resulting in publication bias, influencing the study design, limiting investigators' access to data and having control over publication. In order to address these concerns, the International Committee of Medical Journal Editors (ICMJE) updated its "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." However, a recent study found that U.S. medical schools failed to include provisions in their agreements with industry sponsors of multi-center clinical trials that adhered to the ICMJE guidelines for accountability, access to data and control of publication. Even if ethical guidelines exist and are adopted, they may not be enforced. A recent study found that potential conflicts-of-interest with private industry are rarely reported. Further, it has been argued that guidelines for industry-sponsored research are not sufficient when dealing with the tobacco industry because they do not address the topics of research (i.e., they would not protect against "distracting research"), nor do they address other possible conflict-of-interest relationships between the industry and researchers or their institutions such as the acceptance of donations from these companies. There are also ethical issues arising from the source of tobacco industry research funds – researchers who are sponsored by the tobacco industry must accept that these funds originate directly from the sale of cigarettes, including the sale of cigarettes to minors. In addition, some point out that scientists have a professional obligation to consider how their research findings may be used by others. Scientists who willingly conduct research they know will be beneficial to the objectives of the tobacco industry may be taken to task. Similarly, some may argue that ignorance or naivety is an unsatisfactory defense for those who enter into research relationships with tobacco companies. At this time it is likely that journal submissions and grant proposals that acknowledge current or past relationships with the tobacco industry will be subject to heightened scrutiny.

7. *Funding Eligibility*

One development relevant to this debate is that taking tobacco money could jeopardize eligibility for funding from other sources. Cancer funding agencies, in particular, are beginning to take a hard line on tobacco funding. The National Cancer Institute of Canada, the National Heart Foundation of Australia and some members of the Association of European Cancer Leagues will not fund researchers who receive support from the tobacco industry. Cancer Research UK will not fund researchers if their research institute, university faculty or school receives tobacco funds. This organization is currently reviewing its code of practice on Tobacco Industry Funding to Universities with the aim of taking an even stronger stand. Cancer councils in Australia have taken the strongest position to date: they will not fund individuals if anyone in their institution receives tobacco support. The American Legacy Foundation (Legacy) will not fund applicants that are "in current receipt of any grant monies or in-kind contribution from any tobacco manufacturer, distributor, or other tobacco-related entity, " and expects that grantees

PM3006501338

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

will remain free from tobacco-related contributions for the duration of the grant. In Pennsylvania, institutions receiving tobacco money are ineligible for settlement-based state funding for research and programming. Just as evidence about the negative health impacts of secondhand smoke had a radical effect on the tobacco-control policy debate, the above funding policies also have the potential to quickly lead to changes in university positions about whether individual researchers can choose to accept tobacco industry funds. The academic community will have to address the ethical issues that arise when the actions of one researcher limit the choices of another.

III. Examples of University, Journal and Research Society Policies

There have been no systematic studies exploring the behaviors of individual researchers vis-à-vis accepting research funding from tobacco companies. However, there have been a few studies in which institutions were the unit of analysis. An Australian survey of institutions of higher learning reported that 30% accepted research funds from the tobacco industry in 1991-92, while 2% had institutional policies not to accept research funds from this source. A 1997 study of tobacco associations in the seven New Zealand universities found that five had no formal policies and one had a general policy to disassociate with research that "was not in the public interest." Based on an analysis of papers published from 1988-94, all UK medical schools but one had accepted tobacco money. An early 1990s survey of U.S. medical schools reported that 55% had received research funding from the tobacco industry. A recent study of Canadian universities found that 11% received tobacco research funding from 1996-1999, while none had a policy banning such funding among the faculties of medicine, 25% had received tobacco research funding, and none had a policy to ban acceptance of these funds.

Journals and scientific societies have also debated these issues. The medical section of the American Lung Association, through the American Thoracic Society, has a policy that its two journals will not review papers reporting on research funded by the tobacco industry. The *Journal of Health Psychology* also will not accept articles arising from tobacco industry-sponsored research. The Society for Research on Nicotine and Tobacco does provide membership to tobacco industry scientists as long as they are willing to sign a statement indicating, among other things, that they will "encourage research on public health efforts for the prevention and treatment of cigarette smoking and tobacco use." Still, concerns about the presence of tobacco industry scientists at the Society conferences and on its listserv continue to be raised. Some members may feel that these concerns also extend to academic researchers who accept funding from the tobacco industry. Given that university, journal, research society and funding agency policies regarding tobacco industry-sponsored research are on the increase, it is an opportune time for tobacco control researchers to discuss whether there are any conditions under which acceptance of such funds would be acceptable and, if so, what those conditions might be.

PM3006501339

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

IV. Selected Bibliography

Barnes D.E., Bero L. Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. *Journal of Health Politics, Policy, and Law* 1996;21:515-42.

Barnes D.E., Bero L.A. Scientific quality of original research articles on environmental tobacco smoke. *Tobacco Control* 1997;6:19-26.

Barnes D.E., Bero L.A. Why review articles on the health effects of passive smoking reach different conclusions. *Journal of the American Medical Association* 1998;279:1566-70.

Bero L., Barnes D.E., Hanauer P., Slade J., Glantz S.A. Lawyer control of the tobacco industry's external research program. The Brown and Williamson Documents. *Journal of the American Medical Association* 1995;274:241-247.

Bero L.A., Galbraith A., Rennie D. Sponsored symposia on environmental tobacco smoke. *Journal of the American Medical Association* 1994;271:612-7.

Bloch M. Tobacco industry funding of biomedical research. *Tobacco Control* 1994;3:297-8.

Blum A. Ethics of tobacco-funded research in U.S. medical schools. *Tobacco Control* 1992;1:244-5.

Cancer Research UK. Preventing Lung Cancer: Isolating the Tobacco Industry. Reviewing the Cancer Research UK Code of Practice on Tobacco Industry Funding to Universities. *Consultation Document*. July 2002.

Chapman S., Shatenstein S. The ethics of the cash register: taking tobacco research dollars. *Tobacco Control* 2001;10:1-2.

Cohen Jon. Tobacco money lights up a debate. *Science* 1996;272:488-94.

Cohen J.E. Universities and tobacco money: some universities are accomplices in the tobacco epidemic. *British Medical Journal* 2001;323:1-2.

Cohen J.E, Ashley M.J., Goldstein A.O., Ferrence R., Brewster J.M. Institutional addiction to tobacco. *Tobacco Control* 1999;8:70-4.

Dyer C. Tobacco company set up network of sympathetic scientists. *British Medical Journal* 1998;316:1555.

Fox B.J., Cohen J.E. Tobacco harm reduction: a call to address the ethical dilemmas. *Nicotine & Tobacco Research* (in press).

Gibson B. An introduction to the controversy over tobacco. *Journal of Social Issues* 1997;53:3-11.

Glantz S.A., Barnes D.E., Bero L., Hanauer P., Slade J. Looking through a keyhole at the tobacco industry. The Brown and Williamson documents. *Journal of the American Medical Association* 1995;274:219-24.

Hirschhorn N., Bialous S.A., Shatenstein S. Philip Morris' new scientific initiative: an analysis. *Tobacco Control* 2001;10:247-52.

Hurt R.D. Buying credibility. *Addiction* 1997;92:521-2.

PM3006501340

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Schulman K.A., Seils D.M., Timbie J.W., Sugarman J., Dame L.A., Weinfurt K.P., Mark D.B., Califf R.M. A national survey of provisions in clincial-trial agreements between medical schools and industry sponsors. *New England Journal of Medicine* 2002;347:1335-41.

Turner C., Spilich G.J. Research into smoking or nicotine and human cognitive performance: does the source of funding make a difference? *Addiction* 1997;92:1423-6.

Tweedale G. Science or public relations? The inside story of the Asbestosis Research Council, 1957-1990. *American Journal of Industrial Medicine* 2000;38:723-34.

Walsh R.A., Sanson-Fisher R.W. What universities do about tobacco industry research funding. *Tobacco Control* 1994;3:308-15.

Warner K.E. What's a cigarette company to do? *American Journal of Public Health* 2002;92:897-900.

V. Acknowledgements

The author would like to thank the members of the Tobacco Funding Workshop Planning Committee for their helpful comments on earlier drafts of this backgrounder. The views expressed above do not necessarily reflect those of the planning committee or of the institutions with which the author is affiliated.

Joanna Cohen, Ph.D.
Associate Director, Ontario Tobacco Research Unit
Assistant Professor, Department of Public Health Sciences
University of Toronto
33 Russell Street, T5
Toronto, Ontario
Canada M5S 2S1
Tel: (1) 416-535-8501, ext. 4510
Fax: (1) 416-595-6068

PM3006501341

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

SPEAKER BIOGRAPHIES

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Eisenberg . born 1905

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Disclosure Form Declaration Questions (disclosures included in each bio):

Financial Relationships:

1) Do you currently, or have you in the past 10 years, worked for or been in a financial relationship (contractor, grant recipient, etc.) with a tobacco company or any entity that is affiliated with a tobacco company? If yes, which companies and what was the nature and timeframe of the relationship (e.g., 1994-1996)?

Affiliations:

2) Do you currently have, or have you had in the past 10 years, any other affiliations that should be disclosed to participants (e.g., pharmaceutical company)?

Agree to Publicity Restriction:

3) All participants are restricted from publicizing their invitation to the Tobacco Funding Workshop as an endorsement of their views, organization or company. Do you agree to this restriction?

Linda A. Bailey, J.D., M.H.S.
Director
Center for Tobacco Cessation

Linda Bailey is director of the Center for Tobacco Cessation in Washington, D.C., and an adjunct faculty member at the University of Maryland Law School where she teaches the course, "Tobacco Control and the Law."

Ms. Bailey has a notable career in public health as an attorney, educator and epidemiologist and a strong professional interest in influencing the development of science-based policies promoting health. She was the associate director for the Center for Disease Control and Prevention's Office on Smoking and Health in Washington, D.C., and served as a senior advisor on health promotion and disease prevention at the Office of the Assistant Secretary of Health. Ms. Bailey has also been the study director at the Institute of Medicine, an epidemiologist at the Houston Health Department and a faculty member at Johns Hopkins School of Public Health.

Ms. Bailey holds degrees from Tufts University, Johns Hopkins School of Hygiene and Public Health and University of Maryland School of Law.

Disclosures:

1) Financial Relationships? NO

2) Affiliations? YES

- Non-financial professional affiliations, works with developers of new cessation treatments and considers them colleagues.

3) Agree to Publicity Restriction? YES

PM3006501344

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ronald Bayer, Ph.D.
Professor
Center for the History and Ethics of Public Health
Mailman School of Public Health, Columbia University

Dr. Ronald Bayer is currently a professor at Columbia University and a member of the Institute of Medicine (IOM) Board on Health Promotion and Disease Prevention.

Dr. Bayer was a researcher at the Hastings Center, a research institute devoted to the study of ethical issues in medicine and the life sciences, where he examined ethical and policy issues in public health, focusing on AIDS, tuberculosis, illicit drugs and tobacco. He has also served on IOM committees dealing with tuberculosis elimination, vaccine safety and smallpox vaccination.

Dr. Bayer's articles on AIDS have appeared in the *New England Journal of Medicine*, the *Journal of the American Medical Association*, *The Lancet*, the *American Journal of Public Health*, and *The Milbank Quarterly*. He is also the editor of the Ethics and Policy Forum of the *American Journal of Pubic Health*. Dr. Bayer's books include *Homosexuality and American Psychiatry: The Politics of Diagnosis* (1981), *Private Acts, Social Consequences: AIDS and the Politics of Public Health* (1989); *AIDS in the Industrialized Democracies: Passions, Politics and Policies* (1991, edited with David Kirp); *Confronting Drug Policy: Illicit Drugs in a Free Society* (1993, edited with Gerald Oppenheimer); *Blood Feuds: Blood, AIDS and the Politics of Medical Disaster* (1999, edited with Eric Feldman); and *AIDS Doctors: Voices from the Epidemic*, (2000, written with Gerald Oppenheimer) and *Mortal Secrets: Truth and Lies in the Age of AIDS* (2003, written with Robert Klitzman).

Disclosures:

1) Financial Relationships?	*NO*
2) Affiliations?	*NO*
3) Agree to Publicity Restriction?	*YES*

Neal Benowitz, M.D.
Professor of Medicine, Psychiatry and Biopharmaceutical Services
University of California, San Francisco

Dr. Neal Benowitz is professor of medicine, psychiatry and biopharmaceutical sciences and chief at the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco.

Dr. Benowitz joined the faculty at the University of California, San Francisco in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine, caffeine and cocaine. He served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He has served as president of the American Society for Clinical Pharmacology and Therapeutics and for The Society for Research on Nicotine and Tobacco and served as a member of the National Institute of Health Pharmacology Study Section. Dr. Benowitz is a member of a number of medical societies, including the American Society for Clinical Investigation and the Association of American Physicians.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501345

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Along with publishing over 200 research papers, Dr. Benowitz was also a scientific editor of the United States *Surgeon General's Report on Smoking and Health: Nicotine Addiction*, served as a member of the NIH Pharmacology Study Section and has received the Ove Ferno and the Alton Ochsner awards for his research on nicotine, tobacco and health.

Dr. Benowitz received his M.D. from the University of Rochester School of Medicine and completed a postdoctoral fellowship in clinical pharmacology at the University of California, San Francisco.

Disclosures:

1) Financial Relationships? *YES*

- Received research cigarettes from Philip Morris (1999)

2) Affiliations? *YES*

- Received a recent grant from GlaxoSmithKline
- Serves on Pharmacia advisory board
- Consultant to Novartis
- Consultant to Alexa

3) Agree to Publicity Restriction? *YES*

Lisa A. Bero, Ph.D.
Professor
Center for Tobacco Control Research and Education, Institute for Health Policy Studies,
Department of Clinical Pharmacy
University of California, San Francisco

Dr. Lisa Bero is a pharmacologist with a primary interest in how clinical and basic sciences are translated into clinical practice and health policy. She is director of the Tobacco Center Fellowship Program and vice chair of the Department of Clinical Pharmacy, both at the University of California, San Francisco. She also serves as co-director of the San Francisco Cochrane Center, developing and validating methods for assessing the quality of research and scientific publication and for measuring influences on the quality of research, including university-industry relations.

Dr. Bero has also conducted analyses to examine the dissemination and policy implications of scientific publications. Her international activities include advisor to the World Health Organization Drug Action Programme and Tobacco Free Initiative and advisor to the World Bank. She also serves on several national and international committees related to technology assessment.

Dr. Bero has published numerous peer-reviewed scientific articles related to her research as well as co-authored *The Cigarette Papers* (UC Press, 1996). She was a member of the editorial board of the *British Medical Journal* and an editor for *Tobacco Control* and the Cochrane Effective Practice and Organization of Care Group, an international group of researchers conducting meta-analyses of the literature on interventions to change health professional behavior.

PM3006501346

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

David M. Burns, M.D.
Professor of Medicine
University of California, San Diego

Dr. David Burns is a professor of medicine at the University of California, San Diego School of Medicine.

Dr. Burns has written extensively on issues of the disease consequences of smoking, including modeling of disease risks and projection of those risks with changes in smoking behavior.

Board certified in pulmonary medicine, Dr. Burns trained at the University of California, San Diego School of Medicine from 1976 to 1979. He was medical officer for the National Clearinghouse for Smoking and Health at the Centers for Disease Control of the U.S. Public Health Service. While there, he prepared the 1975 *Surgeon General's Report on the Health Consequences of Smoking* and edited the 1976 Surgeon General's report. Since that time, he has been an author and editor and has reviewed each of the annual reports for the Surgeon General on the health consequences of smoking.

In addition, Dr. Burns has been a consultant for the National Cancer Institute (NCI) and served on the policy advisory committee for the COMMIT trial being conducted by NCI. Dr. Burns also edited a series of tobacco control monographs for the National Cancer Institute. He served on the science advisory board that reviewed the Environmental Protection Agency report, *Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders*, released in 1993. He has also developed several approaches to the use of survey research to evaluate the impact of public policy changes on smoking initiation and cessation.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Testified in tobacco trials against industry
- Periodic honoraria from pharmaceutical companies

3) Agree to Publicity Restriction? *YES*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501347

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Pamela I. Clark, Ph.D.
Senior Research Scientist
Batelle Centers for Public Health Research and Evaluation

Dr. Pamela Clark is a leading expert in state and community approaches to tobacco control. She is experienced in the prevention of adult and youth risk behaviors, particularly in tobacco initiation, maintenance and cessation.

Dr. Clark has been the principal investigator or project director on numerous funded studies using a broad range of study designs. Among her current projects are the first national estimate of illegal tobacco sales to minors using a standardized buying protocol in 2,250 U.S. stores, a controlled laboratory investigation of the differences in biomarkers of exposure among smokers of menthol and non-menthol cigarettes and a comprehensive evaluation of the scientific evidence behind 144 potential indicators of tobacco control program success. Her work is currently funded by the National Center for Environmental Health and the Office on Smoking and Health, both at the Centers for Disease Control, and by the National Cancer Institute.

Dr. Clark is the co-author of two medical textbooks, has contributed chapters to three others, and has published more than 80 papers of medical and public health literature.

Disclosures:

1) Financial Relationships?	*NO*
2) Affiliations?	*NO*
3) Agree to Publicity Restriction?	*YES*

Michael Cummings, Ph.D.
Chairman
Department of Health Behavior, Division of Cancer Prevention and Population Sciences
Roswell Park Cancer Institute

Dr. Michael Cummings is a senior research scientist and chairman of the Department of Health Behavior in the Division of Cancer Prevention and Population Sciences at Roswell Park Cancer Institute in Buffalo, New York. He also holds the position of professor in the Department of Social and Preventive Medicine at the State University of New York at Buffalo where he teaches graduate courses in cancer epidemiology and health behavior.

Dr. Cummings is an internationally recognized authority on tobacco issues. He has contributed to several Surgeon General's reports on smoking and health and to an Institute of Medicine report on nicotine addiction in children. He has testified as an expert witness against the tobacco industry in several cases. His recent work includes studies on tobacco product marketing, the effectiveness of tobacco control policies on adult and youth smoking behavior and consumer risk perceptions about tobacco products and nicotine delivery devices. He is also deputy editor for *Tobacco Control* and has published over 160 scientific papers.

PM3006501348

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Dr. Cummings is a graduate of Miami University in Oxford, Ohio and holds master of public health and doctoral degrees from the University of Michigan at Ann Arbor.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Serves on medical advisory board for the Flight Attendant Medical Research Institute
- Served on scientific advisory boards and medical review committees for the National Institutes of Health, Centers for Disease Control and Prevention, American Cancer Society, Canadian National Cancer Institute, The Robert Wood Johnson Foundation and state and local health agencies
- Received honoraria and accepted hospitality and on a few occasions, travel costs, from pharmaceutical companies making tobacco dependence treatment products
- Receives research funding from the National Cancer Institute, The Robert Wood Johnson Foundation, the American Legacy Foundation and the New York State Department of Health

3) Agree to Publicity Restriction? *YES*

Richard A. Daynard, J.D., Ph.D.
Professor of Law
Northeastern University School of Law

Dr. Richard Daynard has been on the Northeastern University School of Law faculty since 1969, teaching in the areas of consumer protection, strategic litigation and law, policy and society.

Dr. Daynard has been active in tobacco control since the mid-1970's, becoming president of the Tobacco Control Resource Center in 1983 and co-founding the Tobacco Products Liability Project in 1984. He has chaired 20 conferences on tobacco litigation that have drawn national and international participants and has spoken about legal issues in tobacco control in 25 countries. He has been the principal investigator on several research and advocacy grants and has written dozens of articles in this area. He is also a frequent participant in media discussions of tobacco control issues.

Dr. Daynard has been the publisher and editor-in-chief of the *Tobacco Products Litigation Reporter* since 1984. He received a law degree from Harvard, a master's degree in sociology from Columbia and a doctorate in urban studies and planning from Massachusetts Institute of Technology.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501349

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Brion J. Fox, S.M., J.D.
Associate Scientist
University of Wisconsin Comprehensive Cancer Center

Brion Fox is an associate scientist at the University of Wisconsin Comprehensive Cancer Center in Madison where he directs the tobacco ethics and law section of the tobacco control program. His research includes ethics in tobacco control, tobacco industry tactics and translating tobacco science into law and policy. Mr. Fox is also a fellow in The Robert Wood Johnson Foundation's Developing Leadership in Reducing Substance Abuse program.

Mr. Fox is a trained attorney and practiced health and environmental law in Detroit before returning to academia. His transdisciplinary approach to tobacco research has allowed him to participate in many different tobacco related projects, including research on the master settlement agreement and co-authoring and serving as project director for the clinical practice guideline *Treating Tobacco Use and Dependence*. Mr. Fox also serves on the steering committee for the National Tobacco Control Legal Consortium.

He has postdoctoral training in health systems research and preventive oncology.

Disclosures:

1) Financial Relationships? *YES*

- Worked for law firms that represented the industry but did not solicit their business or represent them, 1990-1996

2) Affiliations? *YES*

- Worked for law firms that represented pharmaceutical companies, though did not solicit their business nor work for them on tobacco dependence issues, 1990-1996
- Worked for the Center for Tobacco Research and Intervention that was partially supported by funds from pharmaceutical companies, 1998-2002

3) Agree to Publicity Restriction? *YES*

Phillip S. Gardiner, Dr.P.H.
Social/Behavioral Sciences Research Administrator
Tobacco-Related Disease Research Program
University of California, Office of the President

Dr. Phillip Gardiner is a public health activist, administrator and researcher currently working at the University of California Office of the President as the social/behavioral sciences research administrator for the Tobacco Related Disease Research Program.

For the past 20 years, Dr. Gardiner has worked on studies ranging from hypertension, multiculturalism and AIDS, to breast cancer, prostate cancer and smoking. Throughout his research career, Dr. Gardiner has maintained his community activism to address racial disparities in health. He speaks at numerous

PM3006501350

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

tobacco control and research conferences on the need for greater funding for participatory research and he has strongly advocated for increased research and scrutiny on menthol as an additive to cigarettes. Dr. Gardiner is currently involved in ongoing research as a senior investigator on the San Francisco Family Diabetes Project. The diabetes study is being conducted by the University of California, San Francisco among African and Chinese Americans in the Oakland/San Francisco Bay Area.

Dr. Gardiner recently collaborated on a National Cancer Institute monograph on teen smoking, where he authored a section on African American youth smoking habits. In July of 2000, he authored the article "Mentholated Cigarettes and African-Americans: An Open Question," one factor that helped launch the First Conference on Menthol Cigarettes: Setting the Research Agenda, recently held in Atlanta, Georgia, where he was one of the co-chairs of the conference. He also has authored a newsletter article on tobacco industry philanthropy in the African American community.

Dr. Gardiner received his doctorate from the University of California, Berkeley.

Disclosures:

1) Financial Relationships?	*NO*
2) Affiliations?	*NO*
3) Agree to Publicity Restriction?	*YES*

Stanton A. Glantz, Ph.D.
Professor of Medicine
University of California, San Francisco

Dr. Stanton Glantz has been a leading activist in the nonsmokers rights movement since 1978, when he helped lead a state initiative campaign to enact a nonsmokers rights law by popular vote (defeated by the tobacco industry). In 1983, he helped the successful defense of the San Francisco Workplace Smoking Ordinance against a tobacco industry attempt to repeal it by referendum. The San Francisco victory represented the first electoral defeat of the tobacco industry and is now viewed as a major turning point in the battle for nonsmokers' rights.

Dr. Glantz is one of the founders of Americans for Nonsmokers Rights. He is author or co-author of numerous publications related to nonsmokers rights and tobacco control, as well as several scientific texts and many papers on cardiovascular function and biostatistics. In total, he is the author of 11 books and over 130 scientific papers. His work includes the first major review (published in *Circulation*) that identified involuntary smoking as a cause of heart disease and the landmark July 19, 1995 issue of JAMA on the Brown and Williamson documents, showing that the tobacco industry knew 30 years ago that nicotine was addictive and that smoking caused cancer. This publication was followed up with his book, *The Cigarette Papers*, which has played a key role in the ongoing litigation surrounding the tobacco industry. Dr. Glantz is an associate editor of the *Journal of the American College of Cardiology* and a member of the California State Scientific Review Panel on Toxic Air Contaminants. His work has attracted considerable attention from the tobacco industry, which has sued the University of California twice (unsuccessfully) in an effort to stop Dr. Glantz work.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501351

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Dr. Glantz is currently running two large educational campaigns: "SmokeFreeMovies.ucsf.edu" that is working to end the use of movies to promote tobacco and "TobaccoScam.ucsf.edu" that is countering tobacco industry efforts to co-opt the hospitality industry.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

Rina Hakimian, J.D., M.P.H.
Regulatory Counsel
Division of Biomedical and Health Sciences Research, Association of American Medical Colleges

Rina Hakimian is currently regulatory counsel for the Association of American Medical Colleges (AAMC) in the division of Biomedical and Health Sciences Research.

Ms. Hakimian has just completed a one-year assignment to the National Institutes of Health (NIH)/National Cancer Institute Cancer Diagnosis Program to study legal and ethical aspects of cancer research. While at NIH, she conducted a legislative survey of state and federal laws governing the use of human biological material in research and served as a faculty member to develop the NIH course on protection of human subjects in research.

Prior to joining the AAMC, Ms. Hakimian served as the associate general counsel to the Illinois Institute of Technology where she was legal advisor to its Institutional Review Board (IRB). Ms. Hakimian has been a member of the legal advisory panel of the European Health Telematics Association, advising on legal issues in the field of telemedicine, and a legal expert for the World Association for Medical Law Committee for Patients' Rights. She was also the coordinator for the National Ethics Committee for Human Genetic Research for the Israel Ministry of Health. This committee is similar to an IRB in its review of all biomedical and behavior studies involving human genetic research.

Ms. Hakimian received her bachelor of arts from the University of Pennsylvania, her law degree from Temple University and her master's in public health from the Hebrew University-Hadassah Medical Center.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

PM3006501352

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Cheryl Healton, Dr.P.H.
President and Chief Executive Officer
American Legacy Foundation

Dr. Cheryl Healton is the American Legacy Foundation's first president and chief executive officer.

Dr. Healton is a researcher, professor and public health administrator with more than 20 years experience in public health. She has served on an array of national, state and local committees and task forces for public health and policy issues including HIV/AIDS, violence and alcoholism. She joined Legacy from Columbia University's Joseph L. Mailman School of Public Health in New York where she served as head of the Division of Sociomedical Sciences and associate dean for program development. She founded and directed the school's Center for Applied Public Health, conceptualizing and implementing applied research in emerging issues in public health. Prior to serving as associate dean at the School of Public Health, Dr. Healton was associate dean of Columbia's College of Physicians and Surgeons. In this capacity she was responsible for a wide range of health related programs.

Dr. Healton holds a doctorate from Columbia University's School of Public Health and a master's degree in public administration from New York University for Health Policy and Planning.

Disclosures:

1) Financial Relationships?	*NO*
2) Affiliations?	*NO*
3) Agree to Publicity Restriction?	*YES*

Lynn Kozlowski, Ph.D.
Professor and Head of Department of Biobehavioral Health
Pennsylvania State University

Lynn Kozlowski was awarded a doctorate in psychology by Columbia University in 1975. He was an assistant professor of psychology at Wesleyan University from 1974 to 1979. For 10 years, he worked at the Addiction Research Foundation in Toronto, where he was a senior scientist and head of the behavioral research program on tobacco use. Dr. Kozlowski was also professor of Preventive Medicine and Biostatistics at the University of Toronto. In 1990, he moved to Penn State University where he is now professor and head of the Department of Biobehavioral Health.

Dr. Kozlowski has served on the editorial boards of *Drug and Alcohol Dependence*, *Journal of Substance Abuse* and *Psychology of Addictive Behaviors*. He is an assistant editor of *Addiction*. His research has focused on various aspects of tobacco use including epidemiology, treatment with nicotine replacement therapies, the risks of low-tar cigarettes, filter vent blocking and nicotine addiction. Dr. Kozlowski has contributed to four Surgeon General's reports on smoking and health. He was a founding member of the Society for Nicotine and Tobacco Research and is a fellow of the Society of Behavioral Medicine, Academy of Behavioral Medicine Research and the American Psychological Association.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501353

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Consulted for Pinney Associates
- Received grants from the National Cancer Institute and Centers for Disease Control and Prevention through the Association of Teachers of Preventive Medicine
- Testified against the industry in legal proceedings
- Received a grant from The Robert Wood Johnson Foundation

3) Agree to Publicity Restriction? *YES*

Scott J. Leischow, Ph.D.
Chief, Tobacco Control Research Branch
National Cancer Institute

Dr. Scott Leischow is chief of the Tobacco Control Research Branch in the Behavioral Research Program, Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI).

Prior to taking the NCI position, Dr. Leischow was an associate professor of public health at the College of Public Health, University of Arizona, and director of the Arizona Program for Nicotine and Tobacco Research and co-director of the Biobehavioral Oncology Research Program at the University of Arizona Cancer Center. His research interests include nicotine behavioral pharmacology, tobacco cessation and the translation of clinical smoking cessation research into community practice. In addition to conducting seminal clinical research studies evaluating the safety and efficacy of potential smoking cessation medications, Dr. Leischow also played a senior role in the development of several statewide tobacco treatment and evaluation programs in Arizona, including the creation of the Arizona Smokers Helpline. In 1998, he was named Arizona Prevention Center Researcher of the Year.

Dr. Leischow has received several awards and has published many articles in peer-reviewed journals.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- While working as a consultant and principal investigator, received financial support from several pharmaceutical companies

3) Agree to Publicity Restriction? *YES*

PM3006501354

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Matthew Louis Myers
President and Chief Executive Officer
National Center for Tobacco-Free Kids

Matthew Myers is a nationally recognized tobacco control advocate and has been with the National Center for Tobacco-Free Kids, also known as the Campaign for Tobacco-Free Kids, since its inception in 1996.

Initially, Mr. Myers served as executive vice president and legal counsel for the Campaign for Tobacco-Free Kids and oversaw its advocacy efforts until 1999 when he then became the Campaign's president. The Campaign for Tobacco-Free Kids is a privately funded organization established to focus the nation's attention and action on reducing tobacco use among children. The Campaign seeks to reduce tobacco use by working to create a social and ethical environment that promotes policies supporting a reduction in tobacco use and serves as a resource to others working to reduce tobacco use.

From 1982 to 1996, Mr. Myers represented the Coalition on Smoking or Health, an organization comprised of the American Cancer Society, the American Lung Association and the American Heart Association. He served as its staff director and later as its general counsel. In 1980, Mr. Myers joined the Federal Trade Commission (FTC) in the division of advertising practices and was responsible for the agency's tobacco-related activity. Later, he was named the acting deputy assistant director of the division.

Over the last 20 years, Mr. Myers has participated in virtually every major national tobacco-related legislative effort including successful legislative campaigns to raise the federal excise tax, eliminate smoking on domestic airplane flights, strengthen cigarette health warnings, ban ads for smokeless tobacco on television and require health warnings on smokeless tobacco ads and packages. He has worked with state tobacco control advocates and officials around the country and his legislative advocacy efforts are featured in the book *The Giant Killers* by Michael Pertschuk, former chairman of the FTC.

Mr. Myers is also published widely in health and medical publications and appears often on national news programs to discuss tobacco issues.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- National Center for Tobacco-Free Kids has received donations from GlaxoSmithKline in support of its advocacy work

3) Agree to Publicity Restriction? *YES*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501355

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Charles R. Nesson, J.D.
Weld Professor of Law
Harvard Law School

Charles Nesson is currently on the faculty of the Harvard Law School where he specializes in the law of evidence.

Over the course of his career, Professor Nesson has served as counsel in numerous prominent civil liberties cases, both civil and criminal, and has been the moderator of educational television programs dealing with ethics and the United States Constitution. He is the founder of the Berkman Center for Internet and Society.

Charles Nesson attended Harvard College and Harvard Law School.

Disclosures:

1) Financial Relationships?	*NO*
2) Affiliations?	*NO*
3) Agree to Publicity Restriction?	*YES*

Christopher John Proctor, Ph.D
Head of Science and Regulation
British American Tobacco

Dr. Chris Proctor is the head of Science and Regulation at the British American Tobacco group's (BAT) offices in London.

Dr. Proctor first joined BAT in 1983 as a research scientist, having undertaken postdoctoral research fellowships in physical and environmental chemistry at Cornell University and the University of Kent. Much of his research focused on the topic of environmental tobacco smoke and, in particular, on monitoring real-life exposures. This research has been published in a variety of scientific journals and presented at various scientific conferences.

Dr. Proctor left BAT in 1989 to become a senior scientific advisor to a Washington, D.C. law firm, but returned in 1993. As head of science and regulation, his key interests are developments in the science of smoking and health, and government approaches to improving the quality of regulation. He hosts the company's section on smoking and health on its web site, www.bat.com. On occasion he also presents the company's views on scientific and regulatory matters to governments, the media and other interested parties.

Dr. Proctor has been a member of the European Policy Centre's (EPC) Risk Forum for several years, chaired the steering group of the EPC's consideration of "Regulatory Impact Analysis: Improving the Quality of EU Regulatory Activity" and is currently chairing the steering group of an EPC initiative on risk communication.

PM3006501356

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Disclosures:

1) Financial Relationships? *YES*

- 1993 – Present: Employee, British American Tobacco

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

Nancy Rigotti, M.D.
Director, Tobacco Research and Treatment Center
Massachusetts General Hospital, Harvard Medical School

Dr. Nancy Rigotti is a general internist and practicing primary care physician who has conducted tobacco control research for two decades. She is the founder and director of the Tobacco Research and Treatment Center at Massachusetts General Hospital. This center aims to reduce the prevalence of tobacco use through a combination of clinical care, training and scientific investigation. A major focus is how the health care system can contribute to this goal. The Center's research includes epidemiologic studies of tobacco use, clinical trials of new smoking cessation methods, health services research to disseminate effective treatments and evaluations of tobacco-control public policies such as clean indoor air and youth access.

Dr. Rigotti is president-elect of the Society for Nicotine and Tobacco Research. From 1985 to 1990, she was associate director of the Institute for the Study of Smoking Behavior and Policy at Harvard University. During that time she served as an editor of the 1989 *Surgeon General's Report on Smoking, Reducing the Health Consequences of Smoking: 25 Years of Progress.*

Her work has been recognized by a MidCareer Investigator Award in Patient Oriented Research (K24) from National Heart, Lung and Blood Institute, a Distinguished Professor Award from the Flight Attendants Medical Research Institute, and an award for Innovation in Medical Education from the Society of General Internal Medicine.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Received research grants from GlaxoSmithKline and Elan
- Received honoraria for lectures or short-term consultancy from GlaxoSmithKline, Pharmacia and Pfizer

3) Agree to Publicity Restriction? *YES*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501357

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Dr. Jed E. Rose, Ph.D. (1952 born)
Research Professor
Duke University Medical Center

Dr. Jed Rose is chief of the Nicotine Research Laboratory at the Veterans Administration Medical Center in Durham, North Carolina, and research professor in the department of psychiatry at Duke University.

Dr. Rose is considered one of the leading authorities on the treatment of nicotine addiction. In the early 1980s, Dr. Rose led the initial studies of transdermal nicotine administration that helped pave the way for the development of commercial nicotine skin patches as a smoking cessation treatment. Since then, his research program has continued to develop novel smoking cessation treatments and strives toward a deeper understanding of tobacco dependence. His research is currently applying brain-imaging methodologies, including positron emission tomography and functional magnetic resonance imaging, to identify brain substrates underlying craving and addiction. In addition, Dr. Rose's team has worked to develop smoking cessation treatments involving the use of nicotinic antagonists and various substitution strategies to alleviate craving for cigarettes.

Disclosures:

1) Financial Relationships? *YES*

- Received contracts through Duke University Medical Center from Philip Morris extramural funding program, 2001 – present
- Received unrestricted donations through Duke University Medical Center from Vector Tobacco Company, 2000 – present

2) Affiliations? *YES*

- A patent holder on nicotine patch patent licensed to Novartis Incorporated and nicotine/mecamylamine patch treatment licensed to Elan Corporation

3) Agree to Publicity Restriction? *YES*

David Rosner, M.P.H., Ph.D.
Professor of History and Public Health and Director of the Center for the History and Ethics of Public Health
Columbia University, Mailman School of Public Health

Dr. David Rosner is the current recipient of The Robert Wood Johnson Investigator Award.

Dr. Rosner is the author of *A Once Charitable Enterprise* (Cambridge University Press, 1982; Princeton University Press, 1987), and editor of *Hives of Sickness: Epidemics and Public Health in New York City* (Rutgers University Press, 1995) and *Health Care in America: Essays in Social History* (with Susan Reverby). In addition, he has co-authored and edited numerous books and articles with Gerald Markowitz, the most recent being *Deceit and Denial: The Deadly Politics of Industrial Pollution* (University of California Press and the Milbank Memorial Fund, 2002).

Dr. Rosner was formerly University Distinguished Professor of History at the City University of New York. In addition to numerous grants, he has been a Guggenheim Fellow, a National Endowment for the

PM3006501358

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Humanities Fellow and a Josiah Macy Fellow. He has also been awarded the Distinguished Scholar's Prize from the City University and recently, the Viseltear Prize for Outstanding Work in the History of Public Health from the American Public Health Association (APHA) and the Distinguished Alumnus Award from the University of Massachusetts.

Dr. Rosner received his masters of public health from the University of Massachusetts and his doctorate in the history of science from Harvard.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Hired by state and local governments to act as an expert witness on lead poisoning and children

3) Agree to Publicity Restriction? *YES*

Kathy Sanders-Phillips, Ph.D.
Director of Research Program, Epidemiology and Prevention of Drug Abuse
Howard University

Dr. Kathy Sanders-Phillips is currently the director of the research program in the epidemiology and prevention of drug abuse and professor in the Department of Human Development and Psychoeducational Studies at Howard University.

Prior to Howard, Dr. Sanders-Phillips was a faculty member in the department of pediatrics at University of California, Los Angeles, at the King/Drew Medical Center in Los Angeles and in the School of Public Health at the University of California, Berkeley. At the King/Drew Medical Center, she developed the first house-staff training program in developmental pediatrics that focused on the specific health and psychosocial needs of children of color.

Dr. Sanders-Phillips' research has primarily focused on the impact of exposure to community violence on health behaviors, outcomes and substance use in African American and Latino populations, particularly among children and adolescents. She developed the first research institute in violence research at the King/Drew Medical Center and has published empirical and theoretical articles on the influence of exposure to community violence on psychological distress and health behaviors and decisions in communities of color.

Dr. Sanders-Phillips is currently a member of the advisory board for the Tobacco-Related Disease Research Program at the University of California and for the Substance Abuse Program at The Robert Wood Johnson Foundation. She has served as a member of the National Council for the National Institute on Drug Abuse and as a member of the quality assurance committee to evaluate the NIH research portfolio. She is the former chair of the AIDS Taskforce for the University of California.

Dr. Sanders-Phillips received her doctorate in developmental psychology from Johns Hopkins University.

PM3006501359

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *NO*

3) Agree to Publicity Restriction? *YES*

Richard P. Solana, D.V.M., Ph.D., DABT
Vice President, Worldwide Scientific Affairs
Philip Morris USA, Inc.

Dr. Richard Solana has been with Philip Morris since 1993 and is responsible for conducting a program that effectively applies the understanding of smoking and health science to responsible product development in a transparent and credible way.

Prior to joining Philip Morris USA, Dr. Solana served as chief of the pharmacology division at the U.S. Army Medical Research Institute of Chemical Defense in Aberdeen, Maryland. He also served as consultant to the Army Surgeon General, Pharmacology, and was a delegate to US-USSR (now US-Russia) Bilateral Negotiations on the Destruction and Non-Production of Chemical Weapons.

He has authored and co-written more than 70 scientific publications and abstracts and has received numerous professional honors.

Dr. Solana has a bachelor of science from the United States Air Force Academy, a degree in veterinary medicine from Cornell University and a doctorate in pharmacology and toxicology from the Medical College of Virginia.

Disclosures:

1) Financial Relationships? *YES*

- Employee of Philip Morris USA, 1993 - present

2) Affiliations? *YES*

- Had various pharmaceutical contacts regarding development of drugs for protection against chemical warfare agents, 1993

3) Agree to Publicity Restriction? *YES*

David Sweanor
Legal Counsel
Smoking and Health Action Foundation

David Sweanor is a Canadian lawyer who has worked full time in global tobacco control efforts for 19 years.

PM3006501360

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Mr. Sweanor has played a key role in Canadian efforts on tobacco taxation, advertising restrictions, package labeling, environmental tobacco smoke, cessation, product regulation and other issues. In addition, he has been active on a similar range of global issues, working with bodies such as the International Union Against Cancer, World Health Organization, World Bank, Pan American Health Organization and numerous governments and health agencies.

Mr. Sweanor's primary area of work has been the interaction of law and economics as a determinant of public health, with particular recent emphasis on tax policy, contraband tobacco, the provision of tobacco dependence treatment products and the changing landscape of harm reduction products.

He has been widely published in peer-reviewed scientific journals as well as having authored work for major international health and social service organizations.

Disclosures:

1) Financial Relationships? *YES*

- Rothmans and Imperial Tobacco: nominal shareholder, 1984 – present
- Recently received fees for depositions in U.S. lawsuits from various U.S. companies
- Had confidentiality agreements with two companies seeking to market alternative tobacco products

2) Affiliations? *YES*

- Received payments from pharmaceutical companies that sell or plan to sell smoking cessation medications

3) Agree to Publicity Restriction? *YES*

Kenneth E. Warner, Ph.D.
Avedis Donabedian Distinguished University Professor of Public Health
University of Michigan School of Public Health

Dr. Kenneth Warner is the Avedis Donabedian Distinguished University Professor of public health at the University of Michigan. He has been on the school's faculty since 1972. He is also director of the University's Tobacco Research Network and associate director of the University's Robert Wood Johnson Foundation Clinical Scholars Program.

Dr. Warner is a consultant to numerous governmental bodies, voluntary organizations and businesses and is a member of the board of directors of the American Legacy Foundation.

Presented in 175 professional publications, Dr. Warner's research has focused on economic and policy aspects of disease prevention and health promotion, with a special emphasis on tobacco and health. Dr. Warner served as the senior scientific editor of the 25th anniversary *Surgeon General's Report on Smoking and Health*, published in 1989. He is on the editorial boards of four professional journals and chairs the board of the international journal *Tobacco Control*.

Dr. Warner has been cited twice by Delta Omega, the national public health honorary society, for outstanding achievement in public health. He was awarded the Surgeon General's Medallion by Dr. C.

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501361

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Everett Koop in 1989. In 1990, he received the Leadership Award of the Alcohol, Tobacco and Other Drugs Section of the American Public Health Association. In 1991, Dr. Warner was elected to a four-year term as a senior fellow in the Michigan Society of Fellows. In 1992, the University of Michigan chapter of the Phi Kappa Phi Honorary Society selected him as a faculty honoree. In 1996, he was elected to membership in the Institute of Medicine of the National Academy of Sciences and was named to the first class of fellows of the Association for Health Services Research. In 1997, he received the Excellence in Research Award from the University of Michigan School of Public Health. In 2002, he received the Richard and Barbara Hansen Leadership Award from the University of Iowa College of Public Health. Dr. Warner was a senior fellow at the University of Michigan's Institute of Gerontology from 1989 to 1990, a Kellogg National Fellow from 1980 to 1983 and a visiting scholar at the National Bureau of Economic Research at Stanford University from 1975 to 1976.

Dr. Warner earned his bachelors degree summa cum laude from Dartmouth College and his masters of philosophy and doctorate from Yale University.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Received an honorarium to speak at a conference funded by a pharmaceutical company

3) Agree to Publicity Restriction? *YES*

Mitchell Zeller, J.D.
Vice President for Policy and Strategic Communications
Pinney Associates

Starting in March, 2003, Mitch Zeller will be vice president for policy and strategic communications with Pinney Associates in Bethesda, Maryland.

Since September 2002, Mr. Zeller has been a public health policy consultant, providing strategic planning, regulatory policy and communications advice to a diverse group of clients that includes private sector, nonprofit and advocacy organizations. His consulting projects include regulatory and public health policy issues involving the treatment of tobacco dependence and the regulation of tobacco and alcohol products and pharmaceuticals. Mr. Zeller was also the executive vice president of the American Legacy Foundation where his responsibilities included marketing, communications and strategic partnerships.

Mr. Zeller served as associate commissioner and director of the Food and Drug Administration's Office of Tobacco Programs where he built the first nationwide program to reduce youth access to tobacco and counseled the Human Resources and Intergovernmental Relations Subcommittee of the House Government Operations Committee where he conducted oversight of federal health and safety agencies.

Mr. Zeller has published papers in several leading medical and public health journals including the *New England Journal of Medicine*, and the *Journal of the American Medical Association*.

PM3006501362

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Mr. Zeller has won many awards for his work on tobacco, including the Secretary's Award for Distinguished Service and the National Public Affairs Special Recognition Award from the American Heart Association. He also had the honor of being selected to travel to Moscow on behalf of President Bill Clinton to accept the "World No Tobacco Day" medal from the president of the World Health Organization in recognition of the Clinton Administration's groundbreaking work on tobacco.
Mr. Zeller attended Dartmouth College and is a graduate of the American University Washington College of Law.

Disclosures:

1) Financial Relationships? *NO*

2) Affiliations? *YES*

- Pinney Associates consults with GlaxoSmithKline on cessation and other tobacco related issues

3) Agree to Publicity Restriction? *YES*

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501363

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

FORMS

PM3006501364

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Ethical, Legal and Policy Issues

Tobacco Funding & Scientific Research

Workshop

Evaluation Form

February 22-23, 2003 ***New Orleans***

Thank you for participating in the *Tobacco Funding and Scientific Research Workshop*. We hope you enjoyed the past day and a half as much as we have. Please take a few minutes to answer the following questions about the entire workshop in order to help us better serve you.

1. The workshop was worth my time.

1	2	3	(4)	5
Disagree Strongly				Agree Strongly

2. I learned new ideas that will be useful in the future.

1	2	3	(4)	5
Disagree Strongly				Agree Strongly

3. I made valuable connections with people at the workshop.

1	2	3	4	5
Disagree Strongly				Agree Strongly

4. The conference was professionally organized and seamlessly executed.

1	2	3	(4)	5
Disagree Strongly				Agree Strongly

5. Workshop participants and dialogue were civil and respectful.

1	2	3	(4)	5
Disagree Strongly				Agree Strongly

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501365

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Please rate the following activities on a scale of 1 to 5 by circling one of the ratings in each category.

6. Session 1: Ethical and Legal Perspectives -
Is the tobacco industry different?

Moderator: Dick Daynard *Presenters:* Lisa Bero and Brion Fox

	Poor	Fair	Neutral	Good	Excellent
Overall:	1	2	(3)	4	5
Relevance:	1	(2)	3	4	5
Content:	1	2	(3)	4	5

7. Session 2: Research Funding Practices -
Pro and con perspectives from scientists about taking tobacco industry money

Moderator: Ken Warner *Presenters:* Neal Benowitz and Jed Rose

	Poor	Fair	Neutral	Good	Excellent
Overall:	1	2	3	(4)	5
Relevance:	1	2	3	4	(5)
Content:	1	2	3	(4)	5

8. Socratic Dialogue

Moderator: Charles Nesson

	Poor	Fair	Neutral	Good	Excellent
Overall:	1	2	3	4	5
Relevance:	1	2	3	4	5
Content:	1	2	3	4	5

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501366

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

What did you like best about the workshop?

How could the workshop have been improved?

How will your work be influenced by having attended this workshop?

Please share any suggestions you have for continuing the dialogue initiated at the workshop:

Name: _____

Organization: _____

At the end of the workshop, please drop this evaluation off with the organizers, or mail by March 19, 2003 to the following address:

Pyramid Communications
Attn: Allison Nambu
1932 First Avenue, Suite 507
Seattle, WA 98101
206-792-0437 (phone)
206-374-7798 (fax)
allison@pyramidcommunications.com

Sponsored by the American Legacy Foundation, the National Cancer Institute and the California Tobacco-Related Disease Research Program.

PM3006501367

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

NOTES

PM3006501368

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

02/24/03

Notes:

Leisdown: "Beginning of a dialog"
Scientific integrity; evidence base for use in p.h.

Daynard: lawyer (why do they have so many lawyers making their case?)
"PM said that the multifilter is more safe" -> Robbie

Lisa Bero: 'credibility' = one of 4 criteria used by WSA to evaluate need for sc. research
Publish full data set

Brian Fox: "industry may be sincere to red. harm of their products"
ERP: strengthen focus on product research
-> Business ethics framework to assess companies
recognize "industry" is a set of different companies that change over time
Accepted sc. principles:
- methodological rigor
- transparency
- independence
- open dialogue
- full disclosure of results

Warner: All industries are a-ethical
Government should define the social acceptability of any industry

Benowitz: "Credibility of the Science"
Rose: Pickwarth et al (Henning field): De-nic study
} personal positive examples re ERP

~~Stanton~~: Benowitz: Pharm. ind. approach (cessation products) and tob. ind. developing to safe cig. may eventually merge.

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001

Notes:

Source: https://www.industrydocuments.ucsf.edu/docs/rmhj0001